Meeting
2024 ASCO Annual Meeting
IL33-ST2 axis as a diagnostic and therapeutic biomarker in nivolumab therapy for advanced gastric cancer.
Authors
Chie Kudo-Saito
Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan
Chie Kudo-Saito , Narikazu Boku , Hirokazu Shoji , Hiroshi Imazeki , Kengo Nagashima , Kai Tsugaru , Naoki Takahashi , Takeshi Kawakami , Yusuke Amanuma , Takeru Wakatsuki , Naohiro Okano , Yukiya Narita , Yoshiyuki Yamamoto , Rika Kizawa , Kazunori Aoki , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Biologic Correlates
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4021)
DOI
10.1200/JCO.2024.42.16_suppl.4021
Abstract #
4021
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
First Author: Jingxiao Jin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study).
First Author: Kai Tsugaru
Poster
2018 ASCO Annual Meeting
Regorafenib and nivolumab combination therapy for advanced and metastatic solid tumors: Phase I clinical trial (EPOC1603).
First Author: Shota Fukuoka
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara